Merck Serono's new anticancer cilengitide shows efficacy signal in lung cancer
This article was originally published in Scrip
Executive Summary
Merck Serono's (Merck KGaA) first-in-class anticancer, the integrin inhibitor cilengitide, demonstrated similar median progression-free and overall survival at the highest tested dose as docetaxel chemotherapy in a randomised Phase II trial in second-line non-small cell lung cancer (NSCLC). These findings support its development in the difficult-to-treat disease, according to the company.